Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Benzinga · 4d ago
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.